Page last updated: 2024-12-05

2-aminodiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aminobiphenyl : Any member of the class of biphenyls in which the biphenyl skeleton is substituted by at least one amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7015
CHEMBL ID296021
SCHEMBL ID25981
MeSH IDM0063901

Synonyms (76)

Synonym
AC-19052
BB 0244769
90-41-5
nsc7661
wln: zr br
2-phenylaniline
o-aminodiphenyl
o-phenylaniline
[1,1'-biphenyl]-2-amine
nci-c50282
o-biphenylamine
2-aminobiphenyl
2-biphenylamine
2-aminodiphenyl
nsc-7661
o-aminobiphenyl
AC-907/25014307
NCGC00091135-01
inchi=1/c12h11n/c13-12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9h,13h
biphenyl-2-ylamine
nsc 7661
aminobiphenyl
(1,1'-biphenyl)-2-amine
brn 0471874
ccris 753
einecs 201-990-9
ai3-00067
hsdb 1324
2-aminobifenyl [czech]
2-aminobiphenyl, 97%
biphenyl-2-amine
STK345998
B0467
CHEMBL296021
AKOS000107947
A843537
[1,3]benzoxazolo[2,3-b]quinazolin-12-one;2-aminobiphenyl
NCGC00091135-02
NCGC00091135-03
cas-90-41-5
dtxcid1010189
dtxsid3030189 ,
tox21_200959
NCGC00258512-01
2-biphenylylamine
2-phenylbenzenamine
4-12-00-03223 (beilstein handbook reference)
unii-8lqm58ebry
8lqm58ebry ,
2-aminobifenyl
BP-12718
FT-0611235
CX1301
2-biphenylamine [hsdb]
2-amino-1,1'-biphenyl
AB00375775-03
SCHEMBL25981
1,1'-biphenylamine
2-amino-biphenyl
1,1'-biphenyl-2-ylamine
biphenyl amine
2-amino biphenyl
nci-c50282 (salt/mix)
o-xenylamine
Q-200236
STR00574
mfcd00007701
F2190-0452
2- aminodiphenyl
CS-D1434
BCP16608
Q209308
AMY5191
NCGC00091135-04
EN300-20179
2-amino-1,1 inverted exclamation mark -biphenyl

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" No significant differences in survival times were observed between dosed and control groups."( Carcinogenesis bioassay in rats and mice fed diets containing 2-biphenylamine hydrochloride.
Abdo, KM; Dieter, MP; Haseman, JK; Hildebrandt, P; Huff, JE; Murthy, AS,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency70.57470.007215.758889.3584AID1224835
AR proteinHomo sapiens (human)Potency12.58930.000221.22318,912.5098AID588516
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency40.55330.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.74130.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.61840.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency54.15040.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.39150.000229.305416,493.5996AID588514; AID743069; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency1.72700.001019.414170.9645AID743191
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.001719.739145.978464.9432AID1159509
histone deacetylase 9 isoform 3Homo sapiens (human)Potency59.05840.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.16320.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km47.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1306175Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human MCF7 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1267460Inhibition of recombinant N-terminal truncated human cytosolic 5'-nucleotidase-2 assessed as inhibition of inosine 5'-monophosphate hydrolysis at 1 mM by rapid green malachite assay2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1440872Drug level in human liver microsomes treated with N-(biphenyl-2-yl)-8-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)octanamide after 60 mins by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1306174Therapeutic index, ratio of IC50 for HEK293 cells to IC50 for human HT-29 cells2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306173Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306185Downregulation of VEGFA gene expression in human HT-29 cells assessed as gene expression levels at 15 ug/ml after 48 hrs by RT-qPCR analysis relative to control2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306179Downregulation of VEGFA-165 secretion in human HT-29 cells assessed as protein secretion levels at 15 ug/ml after 72 hrs by ELISA relative to control2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306191Downregulation of TERT gene expression in human HT-29 cells assessed as gene expression levels at 15 ug/ml after 48 hrs by RT-qPCR analysis relative to control2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306171Cytotoxicity against HEK293 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1306172Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID1306197Downregulation of c-Myc gene expression in human HT-29 cells assessed as gene expression levels at 15 ug/ml after 48 hrs by RT-qPCR analysis relative to control2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
Synthesis and evaluation of biphenyl derivatives as potential downregulators of VEGF protein secretion and telomerase-related gene expressions.
AID1440873Drug level in Wistar Han rat liver microsomes treated with N-(biphenyl-2-yl)-8-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)octanamide after 60 mins by LC-ESI-MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (41.67)18.7374
1990's3 (12.50)18.2507
2000's3 (12.50)29.6817
2010's6 (25.00)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]